Retevmo safety and tolerability were evaluated in 702 patients1
- Dose interruptions and dose reductions due to ARs occured in 42% and 31% of patients who received Retevmo, respectively.1 See full Prescribing Information for dose modifications.
- ARs requiring dosage interruption in ≥2% of patients included ALT increased, AST increased, hypertension, diarrhea, pyrexia, and QT prolongation.1
- ARs requiring dosage reductions in ≥2% of patients included ALT increased, AST increased, QT prolongation, and fatigue.1
5% (n=37) of patients discontinued Retevmo (N=702) due to adverse reactions; 2% (n=14) were considered treatment-related, as assessed by trial investigator. Adverse reactions resulting in permanent discontinuation in patients who received Retevmo included increased ALT (0.4%), sepsis (0.4%), increased AST (0.3%), drug hypersensitivity (0.3%), fatigue (0.3%), and thrombocytopenia (0.3%).1,3
Due to rounding and potential double-counting of patients, percentages presented may not add up to the indicated totals.
*Diarrhea, abdominal pain, fatigue, edema, rash, headache, cough, dyspnea, and hemorrhage are consolidated terms. See full Prescribing Information for list of consolidated terms.
†Denominator for each laboratory parameter is based on the number of patients with a baseline and post-treatment laboratory value available, which ranged from 675 to 692 patients.1